v3.26.1
SCHEDULE OF DISAGGREGATION OF REVENUE (Details) - USD ($)
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
DisaggregationOfRevenueLineItem [Line Items]    
Total revenues $ 431,609 $ 136,643
ARBLI Losartan Oral Potassium Suspension [Member]    
DisaggregationOfRevenueLineItem [Line Items]    
Total revenues 431,609
Trxade, Inc. [Member]    
DisaggregationOfRevenueLineItem [Line Items]    
Total revenues $ 136,643